Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026)
Enanta Pharmaceuticals (ENTA) posted Change in Receivables of -$684000.0 for Q1 2026, down 142.46% on a QoQ basis from $1.6 million in Q4 2025, and up 26.13% year-over-year from -$542280.8 in Q1 2025.
Enanta Pharmaceuticals (ENTA) Change in Receivables (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals' Change in Receivables history runs 15 years deep, the most recent figure standing at -$684000.0 for Q1 2026.
- Quarterly Change in Receivables rose 26.13% year-over-year to -$684000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.0 million (up 205.5% YoY) and the FY2025 annual result came in at $236000.0, up 111.99% from the prior year.
- Change in Receivables was -$684000.0 for Q1 2026 at Enanta Pharmaceuticals, down from $1.6 million in the prior quarter.
- Across five years, Change in Receivables topped out at $2.3 million in Q4 2022 and bottomed at -$10.3 million in Q3 2023.
- A 5-year average of -$1.2 million and a median of -$417000.0 in 2024 frame the typical range for Change in Receivables.
- Annual changes were most pronounced in 2023 — Change in Receivables sank 1325.03% — and 2024, when it surged 343.08%.
- Enanta Pharmaceuticals' Change in Receivables stood at $2.3 million in 2022, then sank by 119.45% to -$441000.0 in 2023, then soared by 343.08% to $1.1 million in 2024, then soared by 50.28% to $1.6 million in 2025, then plunged by 142.46% to -$684000.0 in 2026.
- Business Quant data shows ENTA's Change in Receivables at -$684000.0 in Q1 2026, $1.6 million in Q4 2025, and -$1.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Enanta Pharmaceuticals | 376.07 Mn | 212.29 Mn | - | -684,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -684,000.00 |
| Mar 31, 2026 | -684,000.00 |
| Dec 31, 2025 | 1.61 Mn |
| Dec 31, 2025 | 1.61 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Sep 30, 2025 | -1.45 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | -926,000.00 |
| Mar 31, 2025 | -926,000.00 |
| Dec 31, 2024 | 1.07 Mn |
| Dec 31, 2024 | 1.07 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Sep 30, 2024 | -1.53 Mn |
| Jun 30, 2024 | 420,000.00 |
| Jun 30, 2024 | 420,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Mar 31, 2024 | -417,000.00 |
| Dec 31, 2023 | -441,000.00 |
| Dec 31, 2023 | -441,000.00 |